Compare Bristol-Myers Squibb Co (BMY) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs NextEra Energy, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while NextEra Energy, Inc. trades at $89.65 (market cap $186.75B). The key difference: NextEra Energy, Inc. is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | NEE | |
|---|---|---|
Market Cap | $116.30B | $186.75B |
Sector | Health | Utilities |
52-Week High | $62.37 | $97.88 |
52-Week Low | $42.60 | $69.77 |
Enterprise Value | $152.24B | $289.15B |
Dividend Yield | 4.42% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
NextEra Energy (NEE) trades at $88.38, up 0.48% with neutral technical signals. The company shows strong profitability with 29.37% net margin and 15.58% ROE, though revenue growth has been volatile. Recent earnings beat expectations in Q1 2026, with Q2 results due July 24. Analyst consensus is strongly bullish with $103 price target, while technical indicators show RSI at neutral levels with support at $87-88.
NEE presents a compelling utility investment with clean energy leadership and dividend growth potential, though faces risks from capital expenditure demands and regulatory uncertainty. The stock trades below analyst targets with institutional support, but investors should monitor execution on the Dominion deal and AI-driven power demand trends that could impact future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
